Last updated on August 2018

Efficacy and Safety of Lanreotide Autogel (ATG) in Combination With Temozolomide in Subjects With Thoracic Neuroendocrine Tumors.

Brief description of study

The purpose of the protocol is to evaluate the efficacy and safety of Lanreotide ATG 120 mg in combination with Temozolomide in subjects with unresectable advanced neuroendocrine tumours of the lung or thymus as Disease Control Rate at 9 months.

Clinical Study Identifier: NCT02698410

Contact Investigators or Research Sites near you

Start Over

Ipsen Recruitment Enquiries

Oncologia Medica - A.S.L. Brindisi - Presidio Ospedaliero Senatore Antonio Perrino
Brindisi, Italy